|
|
|
| Effect of glibenclamide combined with insulin for treating pregnant women with gestational diabetes mellitus on their pregnancy outcomes and the levels of their Nesfatin-1 and Irisin |
| The Third Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan Province, 450052 |
|
|
|
|
Abstract To explore the effect of glibenclamide combined with insulin for treating pregnant women with gestational diabetes mellitus (GDM) on their pregnancy outcomes and the levels of their Nesfatin-1 and Irisin. Methods: 95 pregnant women with GDM were enrolled in this study and were randomly divided into observation group (n=48) and control group (n=47) according to the serial number of admissions for treatment from August 2018 to December 2019. The women in the control group were subcutaneously injected with insulin before meal for 3 months, while the women in the observation group were given glibenclamide tablets on the basis of the control group for 3 months. The levels of glucose metabolism indexes, Nesfatin-1, and Irisin, the adverse reactions rate, and the pregnancy outcomes of the women were compared between the two groups. Results: After treatment, the levels of glucose metabolism indexes of the women in the two groups had decreased significantly, and which of the women in the observation group were significantly lower than those of the women in the control group. The level of serum Nesfatin-1 of the women in the two groups had decreased significantly, but the Irisin level of the women in the two groups had increased significantly, and the changes range of which of the women in the observation group were significantly better than those of the women in the control group (P<0.05). The incidences of cesarean section, abortion, and premature delivery of the women in the observation group were significantly lower than those of the women in the control group (P<0.05). During treatment, there were adverse events of abnormal liver function, rash, gastrointestinal reactions, and hypoglycemia in both groups, but which no significant different between the two groups (P>0.05). Conclusion: Glibenclamide combined with insulin for treating the pregnant women with GDM can effectively correct their dysfunction of glucose metabolism, reduce the incidence of their adverse pregnancy outcomes, increase their serum Irisin level, and reduce their serum Nesfatin-1 level with good safety of medication.
|
|
|
|
|
|
|
|
|
